HUTCHMED - ADR opened lower at $14.99, compared with its previous close of $15.08. In the last trading session, the stock traded between $14.81 and $15.00. It showed a downward intraday trend.
An investment of $100 made 5 years ago in HUTCHMED - ADR is now worth
$ 48.79
Resulting in a loss of
$ 51.21 (51.21%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.18 (-1.20%)
Day High
$15.00
Day Low
$14.81
Day Open
$14.99
Prev Close
$15.08
Volume
21,870
1W Return
6.89%
1M Return
9.19%
3M Return
19.34%
6M Return
15.77%
1Y Return
-2.24%
Market Cap ($ Mn)
2,599
PE Ratio
123.80
PB Ratio
1.71
PEG Ratio
0.10
ROE
42.55%
ROCE
35.96%
EPS (TTM)
-
1 Week
6.89%
1 Month
9.19%
3 Months
19.34%
6 Months
15.77%
9 Months
-1.40%
HUTCHMED secures US FDA orphan drug status for AIHA treatment
HUTCHMED's sovleplenib received US FDA Orphan Drug Designation for autoimmune hemolytic anemia. This is the second US FDA ODD for sovleplenib, following one for primary immune thrombocytopenia. The drug is eligible for 7 years of US market exclusivity upon regulatory approval. NDAs for sovleplenib are under review by China's NMPA for both ITP and warm AIHA.
7 days agoHutchmed closes GSK license deal, secures $110 million upfront
Hutchmed closed exclusive license deal with GSK for HMPL-A830. Secures $110 million upfront payment from GSK subsidiary. Eligible for up to $1.185 billion in milestone payments. GSK gains worldwide rights excluding Greater China regions. Hutchmed retains Phase I development responsibilities globally.
22 days agoHutchmed partner AstraZeneca files US NDA for lung cancer combo
AstraZeneca submitted US NDA for ORPATHYS plus TAGRISSO combination. SAFFRON Phase III trial showed improved progression-free and overall survival. Targets MET-driven NSCLC patients progressing on EGFR-TKI therapy. Combination already approved in China and authorized in Switzerland.
1mo agoHutchmed initiates global trial of KRAS-EGFR therapy HMPL-A830
Hutchmed initiated Phase Ia global trial for HMPL-A830 on September 27, 2026. First patient dosed in China on September 24, 2026. GSK holds worldwide rights excluding Greater China under September 3 agreement. HMPL-A830 targets KRAS mutations prevalent in up to 89% of pancreatic cancers.
1mo agoHUTCHMED to present positive Phase III lung cancer data at ESMO 2026
HUTCHMED presents positive Phase III data for savolitinib-osimertinib combo at ESMO 2026. SAFFRON global study selected for Presidential Symposium; SANOVO for Proffered Paper. Trials show significant PFS and OS improvements in EGFR-mutated NSCLC patients. Additional updates on fruquintinib and surufatinib across multiple cancer types.
1mo agoHutchmed H1FY26 Results: Oncology revenue rises 23% to $162 million
Oncology revenue rose 23% YoY to $162 million, driven by >40% growth in China product sales. Ex-US FRUZAQLA sales surged 70%, supporting full-year guidance of $330-$450 million. Net income stood at $16 million, excluding prior year's $460 million SHPL divestment gain. R&D expenses increased to $79 million due to AATTC clinical trials and AI investments. Cash reserves remain robust at $1.4 billion amid active collaboration discussions.
1mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $1,437.29 | +0.35% | $13,52,123.38M | 39.43 | |
| $280.41 | -0.13% | $6,75,033.80M | 31.06 | |
| $294.98 | +0.37% | $5,21,411.37M | 72.17 | |
| $147.18 | -0.59% | $3,62,834.91M | 117.74 | |
| $160.32 | -1.80% | $3,26,222.34M | 23.23 | |
| $185.48 | -0.69% | $2,87,691.54M | 24.32 | |
| $468.11 | +0.62% | $2,53,205.85M | 26.86 | |
| $169.73 | -0.67% | $2,10,522.74M | - | |
| $29.45 | +0.31% | $1,67,860.70M | 36.79 | |
| $41.09 | +0.96% | $1,39,300.36M | 11.15 | |
| $62.91 | +0.18% | $1,28,593.45M | 14.67 | |
| $48.43 | +0.41% | $1,16,984.89M | 23.63 |
An investment of $100 made 5 years ago in HUTCHMED - ADR is now worth
$ 48.79
Resulting in a loss of
$ 51.21 (51.21%)
Note: Past profits do not guarantee future returns.
